Vir Biotechnology CEO restructures 467,064 shares

Vir Biotechnology, Inc. director and President & CEO Marianne De Backer reported a restructuring of her common stock holdings.

Rhea-AI Filing Summary

Vir Biotechnology, Inc. director and President & CEO Marianne De Backer reported a restructuring of her common stock holdings. Two Form 4 transactions with code J reclassified a total of 467,064 shares at a stated price of $0.00 per share.

One entry moved 233,532 shares into indirect ownership held by the Ureel-De Backer Family Trust, where she and her spouse serve as trustees, following a transfer without consideration for tax and estate planning purposes. A parallel entry shows 233,532 shares under direct ownership, leaving her with 714,613 directly held shares and 286,650 indirectly held shares after these changes.

Insider Trade Summary

Other: 467,064 shares

Other 2 txns

Insider De Backer Marianne

Role President and CEO

Type	Security	Shares	Price	Value
Other	Common Stock	233,532	$0.00	$0.00
Other	Common Stock	233,532	$0.00	$0.00

Holdings After Transaction: Common Stock — 714,613 shares (Direct); Common Stock — 286,650 shares (Indirect, See Footnote)

Footnotes (2)

1. F1. Transfer without consideration for tax and estate planning purposes.
2. F2. The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.

Key Figures

Restructured shares total: 467,064 shares Shares per transaction: 233,532 shares Direct holdings after transaction: 714,613 shares +3 more

6 metrics

Restructured shares total 467,064 shares Total shares in restructuring transactions coded J

Shares per transaction 233,532 shares Each of the two non-derivative transactions

Direct holdings after transaction 714,613 shares Common Stock held directly after restructuring

Indirect holdings after transaction 286,650 shares Common Stock held indirectly via family trust

Transaction price $0.00 per share Stated price for the reclassified Common Stock

Restructuring share count 467,064 shares Classified as restructuringShares in transaction summary

Key Terms

Form 4, transaction code J, indirect ownership, Ureel-De Backer Family Trust, +1 more

5 terms

Form 4 regulatory

"CEO Marianne De Backer reported these insider changes on Form 4."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code J regulatory

"Both entries use transaction code J for other acquisition or disposition."

indirect ownership financial

"Some shares are reported as indirect ownership through a family trust."

Ureel-De Backer Family Trust financial

"Shares are held by the Ureel-De Backer Family Trust, with her as trustee."

tax and estate planning financial

"The transfer occurred without consideration for tax and estate planning purposes."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vir Biotechnology (VIR) report for Marianne De Backer?

Vir Biotechnology reported a Form 4 for CEO Marianne De Backer showing two code J transactions reclassifying 467,064 common shares. These were transfers without consideration linked to tax and estate planning, affecting how her holdings are split between direct ownership and a family trust.

How many Vir Biotechnology (VIR) shares were affected in this Form 4 filing?

The Form 4 shows 467,064 Vir Biotechnology common shares involved across two transactions of 233,532 shares each. These movements are categorized as “other acquisition or disposition” and reflect internal restructuring of De Backer’s direct and indirect ownership rather than market purchases or sales.

Did Marianne De Backer buy or sell Vir Biotechnology (VIR) stock in this filing?

The filing does not show open-market buying or selling. Instead, both entries use transaction code J, indicating other types of acquisition or disposition. The footnotes describe a transfer without consideration for tax and estate planning rather than a cash purchase or sale.

What is the role of the Ureel-De Backer Family Trust in this Vir Biotechnology (VIR) Form 4?

The Ureel-De Backer Family Trust holds part of Marianne De Backer’s Vir Biotechnology shares as indirect ownership. The Form 4 notes the trust as owner of certain shares and explains that De Backer and her spouse act as trustees, aligning with the tax and estate planning transfer disclosed.

What are Marianne De Backer’s Vir Biotechnology (VIR) holdings after the reported transactions?

After the reported restructuring, the Form 4 lists 714,613 Vir Biotechnology common shares held directly by Marianne De Backer. It also shows 286,650 common shares held indirectly, in the Ureel-De Backer Family Trust, reflecting the updated allocation between her direct and trust holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/30/2026 - 05:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

De Backer Marianne

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026		J(1)		233,532	D	$0	714,613	D
Common Stock	04/29/2026		J(1)		233,532	A	$0	286,650	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transfer without consideration for tax and estate planning purposes.

2. The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)